Surge In Demand For Personalized Medicines Fueling The Growth Of The Market Due To Targeted Treatment Approaches: Critical Driver Shaping the Non-Viral Drug Delivery Systems Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-Viral Drug Delivery Systems Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the non-viral drug delivery systems market has seen significant expansion. The market's value is expected to increase from $8.6 billion in 2024 to a higher $9.84 billion in 2025, presenting a compound annual growth rate (CAGR) of 14.4%. The progressive growth in previous years can be credited to factors such as the rising demand for more reliable gene therapies, advancements in nanotechnology, growing prevalence of chronic diseases, a heightened emphasis on personalized healthcare, and elevated regulatory backing for non-viral platforms.

Non-Viral Drug Delivery Systems Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the size of the non-viral drug delivery systems market is set to experience a significant surge. By 2029, projections indicate that it will expand to $16.72 billion with a Compound Annual Growth Rate (CAGR) of 14.2%. Factors contributing to the growth during this forecast period include the increasing acceptance of targeted therapies, enhanced investments in drug delivery research, a growing inclination towards non-invasive procedures, the inclusion of artificial intelligence, and a higher demand for sustained-release drugs. Future trends during this period encompass the development of nanocarrier technology, the use of superior biomaterials for improved delivery, breakthroughs in mRNA delivery platforms, the incorporation of smart drug delivery devices, and progression in gene editing delivery techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-viral-drug-delivery-systems-global-market-report

What Are the Drivers Transforming the Non-Viral Drug Delivery Systems Market?
The surging need for customized medical treatments is predicted to stimulate the expansion of the non-viral drug delivery systems market. Customized medicine represents a healthcare strategy that adjusts therapy based on a person's genetic profile, lifestyle, and surroundings. The requirement for customized medicine is climbing because it provides more effective therapies by focusing on the distinct origins of disease in each patient. Non-viral mechanisms support personalized medicine by securely delivering drugs or genes to cells, mitigating hazards, and enhancing treatment accuracy. For example, the Personalized Medicine Coalition, an American non-profit organization, stated in February 2024 that the FDA approved 16 new individualized therapies for patients with uncommon diseases in 2023, a rise from six in 2022. Consequently, the escalating demand for individualized medical treatments is fuelling the expansion of the non-viral drug delivery systems market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp

What Long-Term Trends Will Define the Future of the Non-Viral Drug Delivery Systems Market?
Leading enterprises in the non-viral drug delivery system market are concentrating their efforts on cutting-edge technology like pre-optimized ionizable lipid mix systems to expedite the creation and distribution of RNA-based drugs. This system is a formulation method that facilitates the successful padding of RNA molecules into lipid nanoparticles, thereby providing significant stability, payload safety, and targeted delivery for gene-derived drug uses. For instance, in September 2024, Cytiva, a biotechnology firm based in the USA, introduced an RNA delivery LNP kit that is compatible with its NanoAssemblr Ignite and Ignite+ platforms. This kit comes with a ready-for-use ionizable lipid mix that supports swift RNA payload screenings and effective delivery validation, primarily in relation to the development of vaccines against infectious diseases. It fits perfectly with automated microfluidic platforms, permits scalable manufacturing via GMP-grade components, and provides protocols and supporting data to guide users from early discovery to clinical assessment.

Which Segments in the Non-Viral Drug Delivery Systems Market Offer the Most Profit Potential?
The non-viral drug delivery systems market covered in this report is segmented -

1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics

Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp

Which Firms Dominate the Non-Viral Drug Delivery Systems Market by Market Share and Revenue in 2025?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.

Which Regions Offer the Highest Growth Potential in the Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24628

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.